

Supplementary Table S6. Sex-chromosomal differentially methylated CpG sites (DMCs) in the discovery cohort ($p < 1.3 \times 10^{-7}$, $\Delta\beta > |0.05|$, $n=30$) and replication cohort analysing male patients with SLE and male controls. Replication criteria were $p < 6.6 \times 10^{-6}$ ($\alpha=0.05$ divided by 7,625 tests) and same direction of effect. P-values for sites that did not replicate are indicated in italics.

Chr	Position	CpG site	Gene	Discovery*		Replication†	
				p Value	Methylation $\Delta\beta$	p Value	Methylation $\Delta\beta$
X	40007471	cg24618413	<i>BCOR</i>	2.06E-16	-0.060	<i>0.0202</i>	-0.029
X	62972602	cg00369058	<i>ARHGEF9</i>	8.06E-16	0.053	<i>0.0018</i>	0.092
X	70839284	cg07182248	<i>CXCR3</i>	4.33E-14	0.050	<i>0.0255</i>	0.034
X	70326418	cg24655125	<i>CXorf65</i>	5.81E-12	0.074	<i>0.0336</i>	0.033
X	49026774	cg25377867	<i>PLP2</i>	9.12E-12	-0.077	<i>0.495</i>	-0.019
X	40038858	cg19502998	<i>Intergenic</i>	9.13E-12	-0.077	<i>0.0985</i>	-0.043
X	49130160	cg13279286	<i>PPP1R3F</i>	6.85E-11	0.069	<i>4.76E-03</i>	0.043
X	118536722	cg19753067	<i>SLC25A43</i>	1.57E-10	-0.072	<i>3.59E-03</i>	-0.075
X	128724288	cg06055803	<i>OCRL</i>	1.67E-10	-0.089	<i>0.347</i>	-0.027
X	123480277	cg10573235	<i>SH2D1A</i>	2.71E-10	0.103	<i>0.0277</i>	0.047
X	123480594	cg00467547	<i>SH2D1A</i>	3.23E-10	0.054	<i>5.19E-05</i>	0.072
X	39863822	cg27309392	<i>Intergenic</i>	6.88E-10	-0.086	<i>0.361</i>	-0.019
X	70839233	cg12493424	<i>CXCR3</i>	1.22E-09	0.063	<i>1.78E-03</i>	0.057
X	154252341	cg27048639	<i>F8</i>	1.52E-09	-0.071	<i>0.183</i>	-0.038
X	47861943	cg00965330	<i>ZNF182</i>	3.16E-09	-0.076	<i>0.808</i>	-0.006
X	118822815	cg08119631	<i>SEPT6</i>	3.65E-09	0.079	<i>2.06E-06</i>	0.120
X	78201182	cg25420238	<i>P2RY10</i>	5.68E-09	0.091	<i>4.27E-04</i>	0.095
X	123480304	cg25248094	<i>SH2D1A</i>	7.25E-09	0.095	<i>0.128</i>	0.036
X	19689070	cg16399859	<i>SH3KBP1</i>	8.43E-09	-0.069	<i>0.0183</i>	-0.048
X	47490087	cg17662177	<i>CFP</i>	8.44E-09	-0.087	<i>0.0403</i>	-0.050
X	48777487	cg04930858	<i>PIM2</i>	9.12E-09	0.058	<i>1.53E-04</i>	0.097
X	71299647	cg17585445	<i>NHSL2</i>	2.3E-08	-0.052	<i>0.0642</i>	-0.029
X	123479823	cg16928335	<i>SH2D1A</i>	3.43E-08	0.061	<i>4.38E-07</i>	0.092
X	41337610	cg01151305	<i>Intergenic</i>	4.29E-08	0.057	<i>5.97E-06</i>	0.087
X	152682625	cg13976049	<i>ZFP92</i>	5.1E-08	-0.070	<i>1.08E-04</i>	-0.088
X	70521650	cg12391921	<i>ITGB1BP2</i>	5.6E-08	-0.054	<i>5.90E-04</i>	-0.078
X	40016611	cg01110765	<i>BCOR</i>	6.7E-08	-0.070	<i>0.432</i>	0.017
X	40009982	cg10055320	<i>BCOR</i>	6.72E-08	-0.067	<i>0.220</i>	-0.028
X	40009864	cg08156775	<i>BCOR</i>	1.02E-07	-0.071	<i>0.0198</i>	-0.063
Y	15866447	cg08593141	<i>Intergenic</i>	7.99E-09	-0.082	<i>3.24E-04</i>	-0.097

*The discovery cohort included 47 male patients and 49 male control individuals.

†The replication cohort included 26 male SLE patients and 13 male control individuals.